On August 28, 2025 Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, reported that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences (Press release, Keros Therapeutics, AUG 28, 2025, View Source [SID1234655549]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025 Wells Fargo Healthcare Conference

•Date and Time: Thursday, September 4, 2025 at 2:15 p.m. Eastern time
•Link: View Source
•Format: Fireside Chat Presentation

H.C. Wainwright 27th Annual Global Investment Conference

•Date and Time: Tuesday, September 9, 2025 at 12:00 p.m. Eastern time
•Link: View Source
•Format: Corporate Presentation

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of each event.